Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$277.49 +1.9%	$281.03	$253.30 ▼ $346.85	$146.49B	0.51	2.83 million shs	3.69 million shs
BMY Bristol Myers Squibb	$47.04 +0.2%	$48.06	$39.35 ▼ $63.33	$95.49B	0.38	12.97 million shs	14.54 million shs
CMCSA Comcast	$35.21 +1.8%	$34.53	$31.44 ▼ $45.31	$129.15B	0.95	22.02 million shs	24.32 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-5.84%	-7.82%	+0.29%	-11.22%	-11.59%
BMY Bristol Myers Squibb	+0.22%	-3.46%	+0.19%	-20.69%	+12.02%
CMCSA Comcast	+0.17%	-1.48%	+0.20%	-6.36%	-10.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.728 of 5 stars	3.2	4.0	3.3	3.9	2.9	2.5	0.6
BMY Bristol Myers Squibb	4.9419 of 5 stars	3.2	5.0	4.2	4.0	3.0	3.3	1.3
CMCSA Comcast	4.9893 of 5 stars	3.3	5.0	5.0	3.4	4.1	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.38	Hold	$309.22	11.43% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.31% Upside
CMCSA Comcast	2.50	Moderate Buy	$42.10	19.55% Upside

Current Analyst Ratings Breakdown

Latest CMCSA, AMGN, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/6/2025	CMCSA Comcast	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	AMGN Amgen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00
4/28/2025	CMCSA Comcast	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$37.00 ➝ $35.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.46	$30.94 per share	8.97	$10.93 per share	25.39
BMY Bristol Myers Squibb	$48.30B	1.98	$5.90 per share	7.97	$8.08 per share	5.82
CMCSA Comcast	$123.73B	1.06	$8.55 per share	4.12	$22.75 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	25.32	12.97	2.46	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.62	7.72	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
CMCSA Comcast	$16.19B	$4.07	8.65	7.52	1.69	12.72%	19.70%	6.34%	7/22/2025 (Estimated)

Latest CMCSA, AMGN, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	CMCSA Comcast	$1.01	$1.09	+$0.08	$0.89	$29.82 billion	$29.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.43%	N/A	86.86%	14 Years
BMY Bristol Myers Squibb	$2.48	5.27%	N/A	92.88%	17 Years
CMCSA Comcast	$1.32	3.75%	N/A	32.43%	18 Years

Latest CMCSA, AMGN, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/21/2025	CMCSA Comcast	quarterly	$0.33	3.8%	7/2/2025	7/2/2025	7/23/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BMY Bristol Myers Squibb	2.65	1.28	1.17
CMCSA Comcast	1.06	0.65	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
CMCSA Comcast	84.32%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BMY Bristol Myers Squibb	0.07%
CMCSA Comcast	1.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CMCSA Comcast	182,000	3.73 billion	3.69 billion	Optionable

CMCSA, AMGN, and BMY Headlines

Recent News About These Companies

Analysts Conflicted on These Communication Services Names: Alphabet Class A (GOOGL) and Comcast (CMCSA)

June 25 at 12:04 AM | theglobeandmail.com

Investors Heavily Search Comcast Corporation (CMCSA): Here is What You Need to Know

June 24 at 10:00 AM | zacks.com

Invesco LLC Decreases Stake in Comcast Corporation (NASDAQ:CMCSA)

June 24 at 7:22 AM | marketbeat.com

Hi Line Capital Management LLC Raises Position in Comcast Corporation (NASDAQ:CMCSA)

June 24 at 6:57 AM | marketbeat.com

Chevy Chase Trust Holdings LLC Reduces Stake in Comcast Corporation (NASDAQ:CMCSA)

June 24 at 6:38 AM | marketbeat.com

Asset Management One Co. Ltd. Acquires 80,328 Shares of Comcast Corporation (NASDAQ:CMCSA)

June 24 at 5:21 AM | marketbeat.com

Oppenheimer & Co. Inc. Sells 35,623 Shares of Comcast Corporation (NASDAQ:CMCSA)

June 24 at 4:56 AM | marketbeat.com

Comcast’s Q1 Earnings Call: Our Top 5 Analyst Questions

June 23 at 10:21 PM | msn.com

Why Investors Need to Take Advantage of These 2 Consumer Discretionary Stocks Now

June 23 at 9:56 AM | zacks.com

Comcast Opens First Xfinity Store in Tucker, Georgia

June 23 at 9:32 AM | prnewswire.com

Comcast Corporation (NASDAQ:CMCSA) Shares Sold by Scharf Investments LLC

June 23 at 8:04 AM | marketbeat.com

Comcast Corporation (NASDAQ:CMCSA) Shares Bought by Oppenheimer Asset Management Inc.

June 23 at 7:19 AM | marketbeat.com

Comcast Corporation (NASDAQ:CMCSA) Shares Sold by Sawgrass Asset Management LLC

June 23 at 6:28 AM | marketbeat.com

Palumbo Wealth Management LLC Has $2.43 Million Stock Holdings in Comcast Corporation (NASDAQ:CMCSA)

June 23 at 5:59 AM | marketbeat.com

Comcast Corporation (NASDAQ:CMCSA) Shares Acquired by Live Oak Private Wealth LLC

June 23 at 5:23 AM | marketbeat.com

Wolff Wiese Magana LLC Sells 24,679 Shares of Comcast Corporation (NASDAQ:CMCSA)

June 22 at 6:54 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Purchases 16,803 Shares of Comcast Corporation (NASDAQ:CMCSA)

June 22 at 6:20 AM | marketbeat.com

Kentucky Retirement Systems Has $9.45 Million Stock Holdings in Comcast Corporation (NASDAQ:CMCSA)

June 22 at 6:19 AM | marketbeat.com

Synergy Asset Management LLC Sells 142,173 Shares of Comcast Corporation (NASDAQ:CMCSA)

June 22 at 5:47 AM | marketbeat.com

Advisor Resource Council Purchases New Stake in Comcast Corporation (NASDAQ:CMCSA)

June 22 at 4:23 AM | marketbeat.com

Comcast Corporation (NASDAQ:CMCSA) Stock Holdings Lifted by Monte Financial Group LLC

June 21 at 6:50 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMCSA, AMGN, and BMY Company Descriptions

Amgen NASDAQ:AMGN

$277.49 +5.05 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$277.30 -0.19 (-0.07%)

As of 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$47.04 +0.12 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$47.04 +0.00 (+0.01%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Comcast NASDAQ:CMCSA

$35.21 +0.62 (+1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$35.25 +0.04 (+0.11%)

As of 07:56 PM Eastern

Comcast Corporation operates as a media and technology company worldwide. It operates through Residential Connectivity & Platforms, Business Services Connectivity, Media, Studios, and Theme Parks segments. The Residential Connectivity & Platforms segment provides residential broadband and wireless connectivity services, residential and business video services, sky-branded entertainment television networks, and advertising. The Business Services Connectivity segment offers connectivity services for small business locations, which include broadband, wireline voice, and wireless services, as well as solutions for medium-sized customers and larger enterprises; and small business connectivity services in the United Kingdom. The Media segment operates NBCUniversal's television and streaming business, including national and regional cable networks; the NBC and Telemundo broadcast networks and owned local broadcast television stations; and Peacock, a direct-to-consumer streaming services. It also operates international television networks comprising the Sky Sports networks, as well as other digital properties. The Studios segment operates NBCUniversal and Sky film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida; Hollywood, California; Osaka, Japan; and Beijing, China. The company also offers a consolidated streaming platforms under the Philadelphia Flyers and the Wells Fargo Center arena in Philadelphia, Pennsylvania; and Xumo. Comcast Corporation was founded in 1963 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time